Xylem said revenue for the three months ended June 30, 2024 rose to $2,169 million, up $447 million (26.0%), and revenue for the six months rose to $4,202 million, up $1,032 million (32.6%). Organic revenue grew 9.2% and 8.2% over the 3- and 6-month periods, respectively.

10-QQuarterly reportFiled Jul 30, 2024Period of report Jun 30, 2024Summary published (UTC) Oct 23, 2026

Key points

AI summary

Xylem said revenue for the three months ended June 30, 2024 rose to $2,169 million, up $447 million (26.0%), and revenue for the six months rose to $4,202 million, up $1,032 million (32.6%). Organic revenue grew 9.2% and 8.2% over the 3- and 6-month periods, respectively.
The company said operating income for Q2 2024 was $253 million (operating margin of 11.7%), up $134 million from $119 million (6.9%) a year earlier, and adjusted EBITDA was $452 million (margin of 20.8%).
Xylem said operating cash inflow for the 6 months ended June 30, 2024 was $377 million ($9 million in the prior-year period), investing activities used $128 million, and financing activities used $419 million.
The company said total backlog as of June 30, 2024 was $5,156 million, and that it expects about 40% of this backlog to be recognized as revenue in the remainder of 2024. It also outlined full-year 2024 guidance of total revenue growth of 16% and organic revenue growth of 5% to 6%.

Key figures

Quarter ended June 30, 2024

Revenue: $2.2B
Operating income: $253M
Net income: $194M
EPS: $0.80
Gross profit: $819M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q2 2024 Revenue Rises, First-Half Growth

Xylem said revenue for the three months ended June 30, 2024 rose to $2,169 million, up $447 million (26.0%), and revenue for the six months rose to $4,202 million, up $1,032 million (32.6%). Organic revenue grew 9.2% and 8.2% over the 3- and 6-month periods, respectively.

Source · Based on the MD&A text of the filing

Q2 Operating Income and Adjusted EBITDA

The company said operating income for Q2 2024 was $253 million (operating margin of 11.7%), up $134 million from $119 million (6.9%) a year earlier, and adjusted EBITDA was $452 million (margin of 20.8%).

Source · Based on the MD&A text of the filing

First-Half Cash Flow

Xylem said operating cash inflow for the 6 months ended June 30, 2024 was $377 million ($9 million in the prior-year period), investing activities used $128 million, and financing activities used $419 million.

Source · Based on the MD&A text of the filing

Backlog and Full-Year 2024 Outlook

The company said total backlog as of June 30, 2024 was $5,156 million, and that it expects about 40% of this backlog to be recognized as revenue in the remainder of 2024. It also outlined full-year 2024 guidance of total revenue growth of 16% and organic revenue growth of 5% to 6%.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗